Brendan Hannah Purchases 30,845 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) Stock

Quince Therapeutics, Inc. (NASDAQ:QNCX) COO Brendan Hannah bought 30,845 shares of the stock in a transaction dated Wednesday, August 21st. The shares were acquired at an average price of $0.63 per share, for a total transaction of $19,432.35. Following the completion of the purchase, the chief operating officer now directly owns 296,540 shares in the company, valued at $186,820.20. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.

Brendan Hannah also recently made the following trade(s):

• On Monday, August 19th, Brendan Hannah purchased 2,155 shares of Quince Therapeutics stock. The shares were bought at an average price of $0.58 per share, with a total value of $1,249.90.

Quince Therapeutics Stock Performance

QNCX traded up $0.03 during midday trading on Wednesday, reaching $0.64. The company had a trading volume of 203,074 shares, compared to its average volume of 115,453. Quince Therapeutics, Inc. has a 12-month low of $0.51 and a 12-month high of $1.43. The business has a 50-day moving average price of $0.71 and a two-hundred day moving average price of $0.94. The stock has a market cap of $27.66 million, a PE ratio of -0.84 and a beta of 0.94. The company has a debt-to-equity ratio of 0.18, a quick ratio of 7.16 and a current ratio of 7.16.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.